Principal Data & Analytics Engineer
About the job
- At least 8 years of experience in Data Engineering, Analytics Engineering, Data Architecture, Data Platforms, or a closely related discipline.
- Demonstrated experience as a senior technical lead, staff engineer, principal engineer, architect, or equivalent individual contributor with influence across teams.
- Strong hands-on expertise with Snowflake, including data architecture, performance, security, workload management, access patterns, and cost optimization.
- Advanced proficiency in SQL and strong experience with Python for data engineering, automation, platform tooling, or analytical workflows.
- Significant experience with dbt or a comparable SQL-first transformation framework, including project architecture, testing, documentation, deployment, and reusable modeling patterns.
- Experience designing modern analytical data models, including staging layers, conformed dimensions, facts, curated marts, semantic models, and reusable data products.
- Strong knowledge of ingestion, ELT, orchestration, data contracts, schema evolution, data quality, lineage, and production-support practices.
- Experience with Git, automated testing, code review, CI/CD, environment management, and software-engineering practices applied to data systems.
- Experience defining architecture and technical standards while remaining hands-on enough to build prototypes, solve complex problems, and guide implementation.
- Strong written and verbal communication skills, including the ability to explain technical tradeoffs to business and executive audiences.
- Demonstrated ability to mentor engineers and drive technical alignment without formal people-management authority.
- A bachelor's degree in Computer Science, Engineering, Data Science, Information Systems, or a related field, or equivalent practical experience.
- Define and evolve end-to-end architecture across source ingestion, Snowflake, dbt, Omni, Hex, and related data services.
- Translate business strategy and product needs into scalable technical roadmaps, architectural patterns, and platform capabilities.
- Establish technology boundaries and guide where ingestion, transformation, semantic, reporting, and advanced analytical logic should reside.
- Architect secure, scalable, reliable, and cost-effective Snowflake environments supporting data products, business intelligence, self-service analytics, and data science.
- Partner with the Senior Data Engineer on workload management, access patterns, observability, performance, resource utilization, and production support.
- Lead technical strategies for environment management, data access, workload isolation, platform resilience, and ongoing optimization.
- Define standards for SQL, Python, dbt, ingestion pipelines, data modeling, testing, documentation, deployment, and version control.
- Advance Git-based workflows, automated testing, CI/CD, release management, and engineering quality across the data lifecycle.
- Partner with business product owners, data stewards, Analytics Engineers, Data Engineers, and Data Scientists to design trusted and reusable data products.
- Lead root-cause reviews for significant incidents and convert recurring issues into durable platform or engineering improvements.
- Partner with data owners and stewards to implement quality expectations, ownership, lineage, classification, access, and appropriate-use requirements.
- Communicate architecture, risk, tradeoffs, and investment needs to technical teams, business stakeholders, and executive leadership.
- Experience with dltHub or another modern ingestion framework.
- Experience with Omni, Looker, or another governed semantic and business-intelligence platform.
About the company
Curaleaf is a cannabis company that grows, processes, and sells cannabis products for medical and recreational use. It offers items such as tinctures, flowers, and edibles, and uses encapsulation technology to improve product absorption and effectiveness. Customers can buy at dispensaries or online, and the company also provides medical consultations and guidance services. Differentiators include its vertically integrated model (cultivation, processing, and retail) and its social responsibility efforts, such as the B NOBLE program that supports individuals with cannabis-related non-violent charges. The company’s goal is to provide reliable cannabis products and related services to a wide range of customers while advancing responsible access and advocacy through programs like B NOBLE.
Company Size
1,001-5,000
Company Stage
IPO
Headquarters
Stamford, Connecticut
Founded
2010
Get referred to Curaleaf
See people who can refer or advise you
Simplify's Take
What believers are saying
- Q2 2026 revenue reached $340.1 million, up 10%, with $12.5 million net income.
- September 2026 Aurora bid targets Germany's medical cannabis market and four 20 Pharma distribution.
- Curaleaf's Boston opening and Florida expansions add stores, patients, and brand shelf space now.
What critics are saying
- Curaleaf carried $611.5 million debt against $107 million cash on June 30, 2026.
- Aurora's board can stall Curaleaf's $4 hostile bid until the December 1, 2026 deadline.
- Federal illegality keeps Curaleaf exposed to appeals, contract fights, and banking fragility across jurisdictions.
What makes Curaleaf unique
- Curaleaf spans U.S. dispensaries and EU-GMP manufacturing across Germany, Spain, Portugal, and Canada.
- On September 2026, Curaleaf became Spain's first standardized medicinal cannabis registrar under Royal Decree 903/2025.
- Florida remains Curaleaf's scale moat: 77 dispensaries statewide and 178 nationwide on September 4, 2026.
Help us improve and share your feedback! Did you find this helpful?
Benefits
Health Insurance
Dental Insurance
Vision Insurance
Paid Vacation
Parental Leave
401(k) Retirement Plan
Life Insurance
Disability Insurance
Growth & Insights and Company News
6 month growth
0%1 year growth
0%2 year growth
0%Curaleaf Holdings has issued a letter urging Aurora Cannabis shareholders to accept its takeover offer, which represents a 45% premium over Aurora's 30-day volume weighted average price. The acquisition would create a combined company operating across 17 countries with US$1.5 billion in last twelve-month revenue and nearly US$350 million of adjusted EBITDA. Curaleaf Chairman and CEO Boris Jordan framed the decision starkly, describing Aurora as "a shrinking business that is burning cash and getting less profitable by the day." The company expects at least US$40 million in annual cost synergies from the combination. Aurora has refused to engage with Curaleaf's proposal. Jordan announced a live shareholder Q&A session scheduled for 17 September to discuss the offer directly with Aurora investors.
Curaleaf Holdings has opened a new cannabis dispensary in downtown Boston at 21 Milk St., near Downtown Crossing. The location opened on 4 September, offering patients expanded retail space and a broader selection of products. The dispensary will stock Curaleaf's portfolio of cannabis brands, including Dark Heart, Select, FIND, Anthem and Grassroots. Knowledgeable staff will assist customers in selecting products suited to their needs. A grand opening celebration is scheduled for 8 September, featuring in-store promotions, a Meet the Grower event, and brand activations. The store operates from 09:00 to 20:00 Monday through Saturday, and 09:00 to 18:00 on Sunday. The opening follows the closure of Curaleaf's former Provincetown dispensary.
Curaleaf has formally launched its hostile takeover bid for Aurora Cannabis, offering $4 per share directly to shareholders. The offer represents a 45% premium on Aurora's 30-day average share price from 10 August, before Curaleaf announced its intentions. The proposed deal would create a combined company with a $3 billion market cap. Curaleaf projects approximately $40 million in annual cost synergies from the merger. The acquisition aims to give Curaleaf access to EU medical cannabis export markets, particularly Germany. Aurora possesses EU-GMP cultivation capacity that meets strict German import standards. Federal restrictions make direct cannabis exports challenging for US firms like Curaleaf. Curaleaf CEO Boris Jordan said initial friendly discussions with Aurora CEO Miguel Martin earlier this summer stalled, prompting the direct shareholder approach. Aurora's board has formed a special committee to review the offer.
Curaleaf Holdings reported second quarter 2026 revenue of $340 million, representing 10% year-over-year growth driven by domestic and international segments that grew 7% and 26%, respectively. International revenue reached $51 million. The cannabis company posted net income of $12 million and adjusted EBITDA of $70 million, reflecting a 21% margin. Gross profit margin stood at 50%. Chairman and CEO Boris Jordan said the results demonstrate the company's "Built for Growth" strategy is gaining traction. He noted this marks the second consecutive quarter of domestic year-over-year growth. Curaleaf ended the quarter with $107 million in cash and $611.5 million in outstanding debt. The company invested $32.9 million in capital expenditures during the six-month period, focused on facility upgrades and automation.
Curaleaf Holdings has opened its 75th dispensary in Florida, located in Boynton Beach. The cannabis retailer now operates 167 locations nationwide, with Florida representing nearly half of its retail footprint. The new store at 3575 W. Boynton Beach Boulevard is the company's sixth Florida opening this year. It offers medical cannabis products including Anthem pre-rolls, Dark Heart ultra-premium flower, and Select vaping products. Boris Jordan, chairman and CEO, said the opening reinforces Curaleaf's commitment to expanding access to cannabis products across Florida. A grand opening celebration is scheduled for 31 July and 1 August, featuring special promotions and giveaways. The dispensary operates 9:00 to 20:30 Monday through Saturday, and 10:00 to 18:00 on Sunday.